Translational Biomarker Core

$277,988P30FY2019ESNIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications & trials

Paper 39386426 Paper 39354146 Paper 39295102 Paper 39271728 Paper 39201544 Paper 39171784 Paper 39008664 Paper 38958238 Paper 38942346 Paper 38935017 Paper 38909912 Paper 38878851 Paper 38874181 Paper 38827081 Paper 38723657 Paper 38684887 Paper 38588937 Paper 38496553 Paper 38489349 Paper 38481152 Paper 38468492 Paper 38464046 Paper 38417134 Paper 38234818 Paper 38074507 Paper 38063871 Paper 38014131 Paper 38000696 Paper 37992405 Paper 37968231 Paper 37948077 Paper 37945602 Paper 37941438 Paper 37939567 Paper 37937888 Paper 37925128 Paper 37910824 Paper 37898142 Paper 37892309 Paper 37892300 Paper 37891254 Paper 37873172 Paper 37873115 Paper 37866371 Paper 37860069 Paper 37848036 Paper 37847352 Paper 37841071 Paper 37829618 Paper 37820623 Paper 37820223 Paper 37806616 Paper 37802582 Paper 37802579 Paper 37802578 Paper 37802574 Paper 37801602 Paper 37796608 Paper 37772993 Paper 37759736 Paper 37730612 Paper 37728504 Paper 37717994 Paper 37704597 Paper 37703519 Paper 37699202 Paper 37682574 Paper 37651978 Paper 37639477 Paper 37624591 Paper 37605036 Paper 37601414 Paper 37552066 Paper 37546837 Paper 37523031 Paper 37505720 Paper 37475158 Paper 37470831 Paper 37461697 Paper 37435546 Paper 37435521 Paper 37425424 Paper 37419195 Paper 37416871 Paper 37403415 Paper 37399379 Paper 37398224 Paper 37390986 Paper 37376417 Paper 37372761 Paper 37369742 Paper 37368978 Paper 37364682 Paper 37354930 Paper 37350909 Paper 37350870 Paper 37344589 Paper 37333249 Paper 37308721 Paper 37300599

Abstract

Translational Biomarker Core (TBC) Abstract The TBC is a key component of the exposure biology program of the Center of Excellence in Environmental Toxicology (CEET) described in the Strategic Vision. The Core measures biomarkers of exposure and effect, disease onset and progression, and therapeutic response for diseases of environmental etiology. The TBC employs rigorous mass spectrometry (MS)-based methodology to identify biomarkers in cell-culture based models, in animal models and in population and patient cohorts that may be identified in the Integrative Health Sciences Facility Core. Analytes measured are small biomolecules, proteins, as well as targeted and untargeted metabolomes as reporters of the exposome. The TBC recognizes that the need to relate phenotypic changes in biomarkers with either changes in the transcriptome or with genetic variants and this is achieved by data integration performed by the CEET Informatics Core. The integration of genomic, proteomic and metabolomics biomarkers offers the promise to deliver new diagnostic and prognostic indicators that can be used for PREcision Environmental Medicine (PREEM) on an individual basis. The TBC is equipped with state-of-the art liquid chromatography-MS, ultraperformance liquid chromatography (UPLC)-MS and UPLC- high resolution MS instrumentation. Many assays use stable-isotope dilution LC-MS as the gold standard for precision and accuracy and many of the assays cannot be performed elsewhere in the world. The goals of the Core are to (i) analyze biomarkers of exposure and effect in biofluids from model systems and in biofluids in population cohorts and patients; (ii) to provide services in discovery and targeted proteomics and metabolomics; (iii) to develop new assays for CEET investigators and translate these assays into routine Core services for other CEET investigators; and (iv) to provide training to end-users who wish to conduct their own analysis.

View original record on NIH RePORTER →